STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 104472

TO: Christine Saoud **Location: CM1/10E03&10B19** **Art Unit: 1647** **Thursday, September 25, 2003** **Case Serial Number: 09/905348**	**From: Barb O'Bryen** **Location: Biotech-Chem Library** **CM1-6A05** **Phone: 308-4291** **barbara.obryen@uspto.gov**

Search Notes

RUSH

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: September 24, 2003, 18:05:48 ; Search time 41 Seconds
(without alignments)
731.691 Million cell updates/sec

Title: US-09-905-348-18
Perfect score: 1045
Sequence: 1 MTHRTTTWARRTSRAVTPTC.....QVWSVVSPAPSRGQALRRAQ 189

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1045	100.0	189	22	AAB80215	Human PRO232 prote
2	1045	100.0	189	24	ABU69625	Novel human secret
3	1045	100.0	189	24	ABU71448	Human PRO polypept
4	1045	100.0	189	24	ABU71894	Human secreted/tra
5	1045	100.0	189	24	ABU67348	Human secreted pro
6	1045	100.0	189	24	ABU64502	Human secreted/tra
7	1045	100.0	189	24	ABU54350	Human secreted/tra
8	998	95.5	187	20	AAY66174	Human bladder tumo
9	119	11.4	1518	24	ABJ18375	Breast specific re
10	117.5	11.2	277	22	ABU53162	Human testes-deriv
11	117.5	11.2	368	22	ABU53157	Human testes-deriv
12	117.5	11.2	385	22	ABU53156	Human testes-deriv
13	117.5	11.2	386	22	ABU53159	Human testes-deriv
14	117.5	11.2	387	22	ABU53161	Human testes-deriv
15	117.5	11.2	395	22	ABU53160	Human testes-deriv
16	117.5	11.2	717	22	ABU53144	Human testes-deriv
17	117.5	11.2	5179	22	AAM24516	C899P predicted am
18	117.5	11.2	5179	24	ABP55365	Human colon tumour
19	115.5	11.1	1008	22	ABB11527	Human apolipoprote
20	115.5	11.1	1013	22	ABG08112	Novel human diagno
21	114.5	11.0	1247	24	ABJ25815	Aspergillus fumiga
22	114.5	11.0	1263	24	ABJ26415	Aspergillus fumiga
23	114	10.9	1040	22	ABG14734	Novel human diagno
24	111.5	10.7	1012	20	AAY17406	Human atrophin-1 r
25	111.5	10.7	1488	23	ABG97476	Human NAAP10, from
26	111.5	10.7	1568	23	ABG97467	Human NAAP1, from
27	109.5	10.5	693	23	ABP69529	Human polypeptide
28	108	10.3	2009	22	ABG06085	Novel human diagno
29	107.5	10.3	199	23	AAO21814	Lung-specific amin
30	106.5	10.2	351	22	ABG26338	Novel human diagno
31	106	10.1	372	22	AAU48589	Propionibacterium
32	104.5	10.0	19938	24	ABP76679	Streptomyces virid
33	104	10.0	692	22	ABU53155	Human testes-deriv
34	104	10.0	2971	21	AAB41231	Human ORFX ORF995
35	103.5	9.9	214	17	AAR86913	Cotton fiber-speci
36	103.5	9.9	783	19	AAW37151	Mouse neural Mena+
37	103.5	9.9	787	19	AAW37152	Mouse neural Mena+
38	103.5	9.9	802	19	AAW37153	Mouse neural Mena+
39	103.5	9.9	802	22	AAU09139	Mammalian enabled
40	103	9.9	872	23	ABG62165	Human prostate spe
41	103	9.9	1006	23	AAU98904	Human inositol pol
42	103	9.9	1006	24	ABU54583	Human NOVX polypep
43	103	9.9	1328	22	AAM78519	Human protein SEQ
44	103	9.9	1331	22	AAM79503	Human protein SEQ
45	100.5	9.6	1162	21	AAY58500	HHV8 ORF 73 protei

ALIGNMENTS

RESULT 1
AAB80215
ID AAB80215 standard; Protein; 189 AA.
XX
AC AAB80215;
XX
DT 24-APR-2001 (first entry)
XX
DE Human PRO232 protein.
XX
KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW ischaemia; inflammation.
XX
OS Homo sapiens.
XX
PN WO200104311-A1.
XX
PD 18-JAN-2001.
XX
PF 22-FEB-2000; 2000WO-US04414.
XX
PR 07-JUL-1999; 99US-0143048.
PR 26-JUL-1999; 99US-0145698.
PR 28-JUL-1999; 99US-0146222.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 99WO-US00219.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2001-081051/09.
DR N-PSDB; AAF72374.
XX
PT Sixty one nucleic acids encoding PRO polypeptides which are useful in
PT the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
PT squamous cell carcinoma) and neurodegenerative diseases (e.g.
PT Alzheimer's disease) -
XX
PS Claim 1; Fig 9; 393pp; English.
XX
CC The present sequence is one of sixty one novel secreted and
CC transmembrane PRO polypeptides. The PRO polypeptides are
CC useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
CC squamous cell carcinoma), gastrointestinal disorders (e.g.
CC enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
CC Parkinson's disease), wound repair, cardiovascular disorders (e.g.
CC endometrial bleeding angiogenesis, ischaemias such as coronary
CC ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,
CC rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
CC diabetes and retinal disorders such as retinitis pigmentosum.
CC The PRO nucleic acids have applications in molecular biology, including
CC use as hybridization probes, and in chromosome and gene mapping.
XX
SQ Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 22; Length 189;
Best Local Similarity 100.0%; Pred. No. 5.3e-86;
Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189
```

RESULT 2
ABU69625
ID ABU69625 standard; Protein; 189 AA.
XX
AC ABU69625;
XX
DT 05-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO232.
XX
KW Human; secreted and transmembrane protein; gene therapy; psoriasis;
KW enterocolitis; gastrointestinal ulceration; skin disease;
KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;
KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; wound repair; tissue re-growth.
XX
OS Homo sapiens.
XX
PN US2003017463-A1.
XX
PD 23-JAN-2003.
XX
PF 11-JUL-2001; 2001US-0903640.
XX
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063542P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063549P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.

```
PR   29-OCT-1997;   97US-063435P.
PR   29-OCT-1997;   97US-063704P.
PR   29-OCT-1997;   97US-063732P.
PR   29-OCT-1997;   97US-063734P.
PR   29-OCT-1997;   97US-063735P.
PR   29-OCT-1997;   97US-063738P.
PR   29-OCT-1997;   97US-064215P.
PR   31-OCT-1997;   97US-063870P.
PR   31-OCT-1997;   97US-064103P.
PR   03-NOV-1997;   97US-064248P.
PR   07-NOV-1997;   97US-064809P.
PR   12-NOV-1997;   97US-065186P.
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   25-NOV-1997;   97US-066840P.
PR   12-DEC-1997;   97US-069425P.
PR   04-JUN-1998;   98US-088026P.
PR   10-SEP-1998;   98US-099803P.
PR   14-SEP-1998;   98US-100262P.
PR   17-SEP-1998;   98US-100858P.
PR   13-OCT-1998;   98US-104080P.
PR   20-NOV-1998;   98US-109304P.
PR   22-DEC-1998;   98US-113296P.
PR   07-JUL-1999;   99US-143048P.
PR   26-JUL-1999;   99US-145698P.
PR   28-JUL-1999;   99US-146222P.
PR   18-SEP-2000; 2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-341586/32.
DR   N-PSDB; ACA54821.
XX
PT   New PRO polypeptides and nucleic acid molecules, useful in diagnosing
PT   or treating inflammatory diseases, organ failure, atherosclerosis,
PT   cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
PT   Parkinson's disease -
XX
PS   Claim 12; Fig 9; 473pp; English.
XX
CC   The invention describes sixty one nucleic acids encoding PRO polypeptides
CC   (secreted and transmembrane). The PRO polypeptides and nucleic acids are
CC   useful in diagnosing or treating enterocolitis, gastrointestinal
CC   ulceration, skin diseases associated with abnormal keratinocyte
CC   differentiation, e.g. psoriasis or epithelial cancers such as squamous
CC   cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
CC   lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
CC   asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
CC   injury, infertility, birth defects, premature aging, AIDS, cancer,
CC   diabetic complications, or mutations in general. The polypeptides are
CC   also useful for wound repair and associated therapies concerned with
CC   re-growth of tissue. The PRO polypeptides and nucleic acid molecules
CC   are also useful in gene therapy, and as molecular weight markers for
CC   protein electrophoresis purposes. The anti-PRO antibodies may be used
CC   in diagnostic assays for PRO, or for the affinity purification of PRO
CC   from recombinant cell culture or natural sources. This is the amino
CC   acid sequence of a novel human PRO polypeptide.
XX
SQ   Sequence   189 AA;
```

```
  Query Match           100.0%;  Score 1045;  DB 24;  Length 189;
  Best Local Similarity  100.0%;  Pred. No. 5.3e-86;
  Matches  189;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189


RESULT 3
ABU71448
ID   ABU71448 standard; Protein; 189 AA.
XX
AC   ABU71448;
XX
DT   10-JUN-2003  (first entry)
XX
DE   Human PRO polypeptide #4.
XX
KW   Human; secreted and transmembrane protein; PRO polypeptide; cancer;
KW   Alzheimer's disease; ischaemia; cytostatic; nootropic; vasotropic;
KW   neuroprotective.
XX
OS   Homo sapiens.
XX
PN   US2002192659-A1.
XX
PD   19-DEC-2002.
XX
PF   10-JUL-2001; 2001US-0902853.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
```

PR 24-OCT-1997; 97US-062816P.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-361832/34.
DR N-PSDB; ACA58306.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or
PT PRO1868, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy -
XX
PS Claim 12; Fig 9; 474pp; English.
XX
CC The present invention relates to the isolation of novel human secreted
CC and transmembrane proteins (PRO polypeptides), and the polynucleotide
CC sequences encoding them. The polynucleotide sequences are useful in
CC molecular biology, as hybridisation probes, in chromosome and gene
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide sequences may also be used in preparing PRO polypeptides
CC by recombinant techniques, and in generating either transgenic animals
CC or knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptides or
CC their antibodies are useful in preparing a medicament for treating a
CC condition responsive to the polypeptide or antibody, such as cancer,
CC Alzheimer's disease or ischaemia, and in various diagnostic assays.
CC ABU71445-ABU71505 represent human PRO polypeptides of the invention.
XX
SQ Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 24; Length 189;
Best Local Similarity 100.0%; Pred. No. 5.3e-86;
Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189
```

RESULT 4
ABU71894
ID ABU71894 standard; Protein; 189 AA.
XX
AC ABU71894;
XX
DT 12-JUN-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO232.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003003530-A1.
XX
PD 02-JAN-2003.
XX
PF 11-JUL-2001; 2001US-0904011.
XX
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063542P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063549P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-063704P.
PR 29-OCT-1997; 97US-063732P.
PR 29-OCT-1997; 97US-063734P.
PR 29-OCT-1997; 97US-063735P.
PR 29-OCT-1997; 97US-063738P.
PR 29-OCT-1997; 97US-064215P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 03-NOV-1997; 97US-064248P.
PR 07-NOV-1997; 97US-064809P.
PR 12-NOV-1997; 97US-065186P.

```
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   18-SEP-2000; 2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-329602/31.
DR   N-PSDB; ACA60013.
XX
PT   New transmembrane polypeptides and nucleic acids encoding the
PT   polypeptides, useful in gene therapy, in chromosome identification, as
PT   chromosome markers, in generating probes and in tissue typing -
XX
PS   Claim 12; Fig 9; 484pp; English.
XX
CC   The invention relates to an isolated nucleic acid with at least 80%
CC   nucleic acid sequence identity to a nucleotide sequence encoding one of
CC   61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
CC   PRO protein extracellular domain. Also included are a vector comprising
CC   the PRO nucleic acid, a host cell comprising the vector, producing a PRO
CC   polypeptide (by culturing the host cell for the expression of the PRO
CC   polypeptide, and recovering the PRO polypeptide from the cell culture),
CC   an isolated PRO polypeptide (having at least 80% sequence identity
CC   to: ( a) an amino acid sequence selected from the 61 PRO proteins;
CC   (b) an amino acid sequence encoded by a nucleic acid molecule deposited
CC   with an ATCC number (detailed in the specification); or (c) an
CC   extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking
CC   its associated signal peptide), a chimaeric molecule comprising a PRO
CC   polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC   antibody, detecting a PRO245 or PRO1868 in a sample suspected of
CC   containing the polypeptide, linking a bioactive molecule to a cell
CC   expressing a PRO245 or PRO1868 and modulating at least one biological
CC   activity of a cell expressing a PRO245 or PRO1868. Nucleic acids which
CC   encode PRO can be used to generate either transgenic animals or knock-out
CC   animals which may be used in the development and screening of
CC   therapeutically useful reagents. The nucleic acids may also be used in
CC   gene therapy, in chromosome identification, as chromosome markers, or in
CC   generating probes. The PRO polypeptides are useful as molecular markers
CC   for protein electrophoresis, and the isolated nucleic acids may be used
CC   for recombinantly expressing those markers. The PRO polypeptides and
CC   nucleic acids may also be used in tissue typing. Anti-PRO antibodies
CC   are useful in diagnostic assays for PRO, and in affinity purification
CC   of PRO from recombinant cell culture or natural sources. The
CC   present sequence represents a PRO protein.
XX
SQ   Sequence   189 AA;

  Query Match             100.0%;  Score 1045;  DB 24;  Length 189;
  Best Local Similarity   100.0%;  Pred. No. 5.3e-86;
  Matches  189;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189


RESULT 5
ABU67348
ID   ABU67348 standard; Protein; 189 AA.
XX
AC   ABU67348;
XX
DT   29-MAY-2003  (first entry)
XX
DE   Human secreted protein PRO232.
XX
KW   Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;
KW   psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;
KW   Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;
KW   atrophia areata; inflammatory disease; asthma; rheumatoid arthritis;
KW   ischaemia.
XX
OS   Homo sapiens.
XX
PN   US2003023054-A1.
XX
PD   30-JAN-2003.
XX
PF   16-JUL-2001; 2001US-0906742.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   11-FEB-2000; 2000WO-US03565.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   22-MAY-2000; 2000WO-US14042.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   24-AUG-2000; 2000WO-US23328.
PR   17-SEP-1997;   97US-059113P.
PR   17-SEP-1997;   97US-059115P.
PR   17-SEP-1997;   97US-059117P.
PR   17-SEP-1997;   97US-059119P.
PR   17-SEP-1997;   97US-059121P.
PR   17-SEP-1997;   97US-059122P.
PR   17-SEP-1997;   97US-059184P.
PR   18-SEP-1997;   97US-059263P.
PR   18-SEP-1997;   97US-059266P.
PR   15-OCT-1997;   97US-062125P.
PR   17-OCT-1997;   97US-062285P.
PR   17-OCT-1997;   97US-062287P.
```

```
PR   21-OCT-1997;   97US-063486P.
PR   24-OCT-1997;   97US-062814P.
PR   24-OCT-1997;   97US-062816P.
PR   24-OCT-1997;   97US-063045P.
PR   24-OCT-1997;   97US-063120P.
PR   24-OCT-1997;   97US-063121P.
PR   24-OCT-1997;   97US-063127P.
PR   24-OCT-1997;   97US-063128P.
PR   27-OCT-1997;   97US-063327P.
PR   27-OCT-1997;   97US-063329P.
PR   28-OCT-1997;   97US-063541P.
PR   28-OCT-1997;   97US-063542P.
PR   28-OCT-1997;   97US-063544P.
PR   28-OCT-1997;   97US-063549P.
PR   28-OCT-1997;   97US-063550P.
PR   28-OCT-1997;   97US-063564P.
PR   29-OCT-1997;   97US-063435P.
PR   29-OCT-1997;   97US-063704P.
PR   29-OCT-1997;   97US-063732P.
PR   29-OCT-1997;   97US-063734P.
PR   29-OCT-1997;   97US-063735P.
PR   29-OCT-1997;   97US-063738P.
PR   29-OCT-1997;   97US-064215P.
PR   31-OCT-1997;   97US-063870P.
PR   31-OCT-1997;   97US-064103P.
PR   03-NOV-1997;   97US-064248P.
PR   07-NOV-1997;   97US-064809P.
PR   12-NOV-1997;   97US-065186P.
PR   17-NOV-1997;   97US-065846P.
PR   18-NOV-1997;   97US-065693P.
PR   21-NOV-1997;   97US-066120P.
PR   21-NOV-1997;   97US-066364P.
PR   24-NOV-1997;   97US-066453P.
PR   24-NOV-1997;   97US-066466P.
PR   24-NOV-1997;   97US-066511P.
PR   24-NOV-1997;   97US-066770P.
PR   24-NOV-1997;   97US-066772P.
PR   25-NOV-1997;   97US-066840P.
PR   12-DEC-1997;   97US-069425P.
PR   04-JUN-1998;   98US-088026P.
PR   10-SEP-1998;   98US-099803P.
PR   14-SEP-1998;   98US-100262P.
PR   17-SEP-1998;   98US-100858P.
PR   13-OCT-1998;   98US-104080P.
PR   20-NOV-1998;   98US-109304P.
PR   22-DEC-1998;   98US-113296P.
PR   07-JUL-1999;   99US-143048P.
PR   26-JUL-1999;   99US-145698P.
PR   28-JUL-1999;   99US-146222P.
PR   18-SEP-2000;  2000US-0665350.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi A,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi JC,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
DR   WPI; 2003-331485/31.
DR   N-PSDB; ACA05351.
XX
PT   Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g.
PT   PRO245 or PRO1868, useful in chromosome and gene mapping, in generating
PT   antisense RNA and DNA, and in treating cancer and Alzheimer's disease -
XX
PS   Example 4; Fig 9; 481pp; English.
XX
CC   The invention relates to sixty one nucleic acids encoding PRO
CC   polypeptides (secreted and transmembrane). The polynucleotide is useful
CC   in molecular biology, including uses as hybridisation probes, in
CC   chromosome and gene mapping, in generating antisense RNA and DNA, and in
CC   gene therapy. The polynucleotide may also be used in preparing PRO
CC   polypeptides by recombinant techniques, and in generating either
CC   transgenic animals or knock-out animals which, in turn, are useful in the
CC   development and screening of therapeutically useful reagents. The PRO
CC   polypeptide or the antibody is used in preparing a medicament for
CC   treating a condition responsive to the polypeptide or antibody, such as
CC   mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g.
CC   psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease
CC   e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome,
CC   atrophia areata, angiogenesis, inflammatory disease e.g asthma and
CC   rheumatoid arthritis, ischaemia, and in various diagnostic assays. The
CC   present sequence represents the amino acid sequence of a PRO polypeptide.
XX
SQ   Sequence   189 AA;

  Query Match            100.0%;  Score 1045;  DB 24;  Length 189;
  Best Local Similarity  100.0%;  Pred. No. 5.3e-86;
  Matches  189;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189


RESULT 6
ABU64502
ID   ABU64502 standard; Protein; 189 AA.
XX
AC   ABU64502;
XX
DT   13-MAY-2003  (first entry)
XX
DE   Human secreted/transmembrane protein, #5.
XX
KW   Human; PRO; secreted; transmembrane; pharmaceutical;
KW   diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;
KW   endometriosis; cancer; tumour; ischaemia; coronary arterial disease;
KW   polycystic kidney disease; renal failure; inflammatory response; asthma;
KW   rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;
KW   cytostatic; gynecological; cardiant; nephrotropic; hepatotropic;
KW   antiinflammatory.
XX
OS   Homo sapiens.
XX
PN   US2002160374-A1.
XX
PD   31-OCT-2002.
XX
PF   12-JUL-2001; 2001US-0905291.
XX
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19177.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   01-DEC-1998;   98WO-US25108.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
```

PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063542P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063549P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-063704P.
PR 29-OCT-1997; 97US-063732P.
PR 29-OCT-1997; 97US-063734P.
PR 29-OCT-1997; 97US-063735P.
PR 29-OCT-1997; 97US-063738P.
PR 29-OCT-1997; 97US-064215P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 03-NOV-1997; 97US-064248P.
PR 07-NOV-1997; 97US-064809P.
PR 12-NOV-1997; 97US-065186P.
PR 17-NOV-1997; 97US-065846P.
PR 18-NOV-1997; 97US-065693P.
PR 21-NOV-1997; 97US-066120P.
PR 21-NOV-1997; 97US-066364P.
PR 24-NOV-1997; 97US-066453P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066511P.
PR 24-NOV-1997; 97US-066770P.
PR 24-NOV-1997; 97US-066772P.
PR 18-SEP-2000; 2000US-0665350.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-288105/28.
DR N-PSDB; ABX96030.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)
PT and genes encoding them, useful for detecting or treating e.g.
PT hyperplasia, endometriosis, cancers, ischemia, coronary arterial
PT disease or inflammations -
XX
PS Claim 12; Fig 9; 477pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to
CC raise antibodies that specifically bind to the PRO polypeptide, for
CC linking a bioactive molecule to a cell expressing a PRO protein and for
CC modulating at least one biological activity of a cell. The PRO
CC polypeptides or polynucleotides are also useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors, for detecting or treating e.g.
CC hyperplasia, endometriosis, cancers (e.g. those involving solid tumours),
CC ischaemia, coronary arterial disease, polycystic kidney disease, chronic
CC or acute renal failure, or inflammatory responses (e.g. asthma,
CC rheumatoid arthritis, psoriasis or multiple sclerosis) in mammals. The
CC PRO genes may also be used in gene therapy, particularly for replacing a
CC defective gene. The sequences presented in ABU64499-ABU64559 are the
CC PRO polynucleotides of the invention.
XX
SQ Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 24; Length 189;
Best Local Similarity 100.0%; Pred. No. 5.3e-86;
Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189
```

RESULT 7
ABU54350
ID ABU54350 standard; Protein; 189 AA.
XX
AC ABU54350;
XX
DT 10-MAR-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO232.
XX
KW Human; PRO; secreted protein; transmembrane protein; enterocolitis;
KW gastrointestinal ulceration; skin disease;
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;
KW amyotrophic lateral sclerosis; inflammatory disease;
KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;
KW atherosclerosis; cardiac injury; infertility; birth defect;
KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;
KW diabetic complication; wound repair.
XX
OS Homo sapiens.
XX

PN US2002132240-A1.
XX
PD 19-SEP-2002.
XX
PF 18-JUL-2001; 2001US-0909320.
XX
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 06-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-147434/14.
DR N-PSDB; ABX71461.
XX
PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing
PT or treating inflammatory diseases, organ failure, atherosclerosis,
PT cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
PT Parkinson's disease -
XX
PS Claim 12; Fig 9; 473pp; English.
XX
CC The invention relates to an isolated PRO polypeptide having at least 80%
CC amino acid sequence identity to: (a) any one of 61 fully defined amino
CC acid sequences given in the specification (appearing as ABU54347-
CC ABU54407); (b) an amino acid sequence encoded by the nucleotide sequence
CC deposited under American Type Culture Collection (accession numbers
CC listed in the specification); (c) any one of the PRO sequences which
CC lacks its associated signal peptide; (d) an extracellular domain of the
CC PRO polypeptide with its associated signal peptide; or (e) an
CC extracellular domain of the PRO polypeptide which lacks its associated
CC signal peptide. Also include are the nucleic acids encoding the PRO
CC polypeptides, vectors, host cells and anti-PRO antibodies.
CC The PRO polypeptides and nucleic acids are useful in diagnosing
CC or treating enterocolitis, gastrointestinal ulceration, skin diseases
CC associated with abnormal keratinocyte differentiation, e.g. psoriasis
CC or epithelial cancers such as squamous cell carcinoma, Alzheimer's
CC disease, Parkinson's disease, amyotrophic lateral sclerosis,
CC inflammatory diseases, e.g. rheumatoid arthritis, asthma or multiple
CC sclerosis, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, AIDS, cancer, diabetic complications,
CC or mutations in general. The polypeptides are also useful for wound
CC repair and associated therapies concerned with re-growth of tissue. The
CC nucleotide sequences may be used as hybridisation probes in chromosome
CC and gene mapping, or in generating antisense RNA and DNA. PRO nucleic
CC acids are also useful in preparing PRO polypeptides, in assays to
CC identify other proteins or molecules involved in binding reaction, to
CC generate transgenic animals or knockout animals, which in turn are
CC useful in the development and screening of therapeutically useful
CC reagents, for chromosome identification, and tissue typing. The PRO
CC polypeptides and nucleic acid molecules are also useful in gene
CC therapy, and as molecular weight markers for protein electrophoresis
CC purposes. The anti-PRO antibodies may be used in diagnostic assays for
CC PRO, or for the affinity purification of PRO from recombinant cell
CC culture or natural sources. The present sequence represents a PRO
CC polypeptide.
XX
SQ Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 24; Length 189;
Best Local Similarity 100.0%; Pred. No. 5.3e-86;
Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTHRTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQ 60

Qy         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQIS 120

Qy        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SSDTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPS 180

Qy        181 RGQALRRAQ 189
              |||||||||
Db        181 RGQALRRAQ 189
```

RESULT 8
AAY66174
ID AAY66174 standard; Protein; 187 AA.
XX
AC AAY66174;
XX
DT 14-FEB-2000 (first entry)
XX
DE Human bladder tumour EST encoded protein 32.
XX
KW Expressed sequence tag; human; bladder; tumour; cancer; cytostatic;
KW treatment; gene therapy; EST.
XX
OS Homo sapiens.
XX
PN DE19818619-A1.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1998; 98DE-1018619.
XX
PR 21-APR-1998; 98DE-1018619.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-612028/53.
XX
PT New nucleic acid sequences expressed in bladder tumor tissue, and
PT derived polypeptides, for treatment of bladder tumor and identification
PT of therapeutic agents -
XX

```
PS   Claim 23; Page 111; 132pp; German.
XX
CC   This invention describes novel polypeptide fragments (I) and the
CC   polynucleotides (II) that encode them that are highly expressed in a
CC   human bladder tumour and which have cytostatic activity. (II) are used
CC   for recombinant expression of (I) and to isolate complete genes. (I) are
CC   used to identify agents suitable for treatment of bladder cancer, to
CC   directly treat this form of cancer (including expression from gene
CC   therapy vectors) or are used in a preparation for cancer treatment. (I)
CC   is also used for the generation of specific antibodies. (II) are
CC   identified by assembling ESTs (expressed sequence tags) from a
CC   particular tissue type before comparison of expression patterns. This
CC   allows a significantly longer fragment of the gene to be revealed, and
CC   therefore reduces the number of failures associated with the fact that
CC   ESTs from different libraries may represent different parts of the same
CC   unknown gene, distorting the estimated frequency of occurrence in a
CC   particular tissue. AAY66143-Y66198 represent protein fragments encoded by
CC   the human bladder tumour cDNA library derived expressed sequence tag
CC   (EST) fragments represented in AAZ43260-Z43309.
XX
SQ   Sequence   187 AA;

  Query Match             95.5%;  Score 998;  DB 20;  Length 187;
  Best Local Similarity   97.8%;  Pred. No. 8.7e-82;
  Matches  182;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          4 RTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 63
              |    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 RAARGARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 61

Qy         64 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 123
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 121

Qy        124 TDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 183
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        122 TDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 181

Qy        184 ALRRAQ 189
              ||||||
Db        182 ALRRAQ 187


RESULT 9
ABJ18375
ID   ABJ18375 standard; Protein; 1518 AA.
XX
AC   ABJ18375;
XX
DT   30-JAN-2003  (first entry)
XX
DE   Breast specific related amino acid sequence SEQ ID No 184.
XX
KW   Cytostatic; BSP-agonist; BSP-antagonist; vaccine; gene therapy; cancer;
KW   metastatic; breast cancer; breast specific; human.
XX
OS   Homo sapiens.
XX
PN   WO200277232-A2.
XX
PD   03-OCT-2002.
XX
PF   21-NOV-2001; 2001WO-US43815.
XX
PR   22-NOV-2000; 2000US-252509P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Salceda S,  Macina RA,  Recipon H,  Pluta J,  Sun Y,  Liu C;
XX
DR   WPI; 2003-018927/01.
XX
PT   New isolated nucleic acid molecule, useful for treating breast cancer,
PT   and diagnosing or monitoring the presence of metastases of breast
PT   cancer in a patient  -
XX
PS   Claim 11; Page 313-320; 377pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid molecule
CC   comprising: a sequence encoding a sequence comprising 11-1518 amino
CC   acids; a sequence comprising 190-8144 bp; or a sequence that selectively
CC   hybridises to, or having at least 60% identity with the 11-1518 amino
CC   acid or 190-8144 nt sequence. The polypeptide and the nucleic acid are
CC   useful for treating breast cancer, and diagnosing or monitoring the
CC   presence of metastases of breast cancer in a patient. The polynucleotides
CC   of the invention can be used to treat disorders by gene therapy. This
CC   sequence represents a breast specific related polypeptide of the
CC   invention.
XX
SQ   Sequence   1518 AA;

  Query Match             11.4%;  Score 119;  DB 24;  Length 1518;
  Best Local Similarity   28.9%;  Pred. No. 0.072;
  Matches   56;  Conservative   19;  Mismatches   79;  Indels   40;  Gaps    8;

Qy          3 HRTTTWARRTSRAVT--PTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPL 59
              | |   :|  ||  :   |   |  | |  : ||:|          |  :      :
Db        744 HPTRPPSRPPSRPQSVSRPPSEPPLHPCPPPQAPPTL----------PGIF-----VI 786

Qy         60 QPTLGVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQI 119
              |  ||| | || |  |     :| | |:: |          |:| | | :  | | :
Db        787 QNQLGVPPPASNPAPTAPGPPQPPLRPQSQPPEG-------PLP-PAPHLPPSSTSSAVA 838

Qy        120 SSSDTDP--PADGPSN------PLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQV 171
              |||:|    ||  ||:      |      ||  |   |   || |: | |  |      |:
Db        839 SSSETSSRLPAPTPSDFQLQFPP----SQGPHKSPTPPPTLHLVPEPAAPPPPPPRTFQM 894

Qy        172 WSVVSPAPSRGQAL 185
              :   ||  : :||
Db        895 VTTPFPALPQPKAL 908


RESULT 10
ABU53162
ID   ABU53162 standard; Protein; 277 AA.
XX
AC   ABU53162;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human testes-derived DKFZphtes3_2a11 homologue #22.
XX
KW   Human; gene therapy; vaccine; disease treatment; detection.
XX
OS   Homo sapiens.
XX
PN   WO200112659-A2.
XX
PD   22-FEB-2001.
XX
PF   18-AUG-2000; 2000WO-IB01496.
XX
PR   18-AUG-1999;   99US-0149499.
PR   28-SEP-1999;   99US-0156503.
XX
PA   (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI   Wiemann S;
XX
DR   WPI; 2001-327840/34.
XX
PT   Nucleic acids having the sequences of clones isolated from libraries of
PT   different human tissues, useful in recombinant DNA methodologies -
XX
PS   Example III; Page 775; 1095pp; English.
XX
```

CC This invention describes novel polynucleotides and polypeptides isolated
CC from human cDNA libraries which can be used for gene therapy or in
CC vaccines. The polynucleotides of the invention and antibodies encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. The products of the
CC invention may also be used to identify modulators of expression and
CC activity and to down regulate expression and activity. The antibodies of
CC the invention may also be used as diagnostic agents for detecting the
CC presence of polypeptides in samples. This sequence represents a homologue
CC of a polypeptide described in the disclosure of the invention.
XX
SQ Sequence 277 AA;

Query Match 11.2%; Score 117.5; DB 22; Length 277;
Best Local Similarity 23.2%; Pred. No. 0.015;
Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5;

Qy 5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64
Db 104 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 161

Qy 65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122
Db 162 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 216

Qy 123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179
Db 217 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 267

RESULT 11
ABU53157
ID ABU53157 standard; Protein; 368 AA.
XX
AC ABU53157;
XX
DT 14-APR-2003 (first entry)
XX
DE Human testes-derived DKFZphtes3_2a11 homologue #17.
XX
KW Human; gene therapy; vaccine; disease treatment; detection.
XX
OS Homo sapiens.
XX
PN WO200112659-A2.
XX
PD 22-FEB-2001.
XX
PF 18-AUG-2000; 2000WO-IB01496.
XX
PR 18-AUG-1999; 99US-0149499.
PR 28-SEP-1999; 99US-0156503.
XX
PA (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI Wiemann S;
XX
DR WPI; 2001-327840/34.
XX
PT Nucleic acids having the sequences of clones isolated from libraries of
PT different human tissues, useful in recombinant DNA methodologies -
XX
PS Example III; Page 773-774; 1095pp; English.
XX
CC This invention describes novel polynucleotides and polypeptides isolated
CC from human cDNA libraries which can be used for gene therapy or in
CC vaccines. The polynucleotides of the invention and antibodies encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. The products of the
CC invention may also be used to identify modulators of expression and
CC activity and to down regulate expression and activity. The antibodies of
CC the invention may also be used as diagnostic agents for detecting the
CC presence of polypeptides in samples. This sequence represents a homologue
CC of a polypeptide described in the disclosure of the invention.
XX
SQ Sequence 368 AA;

Query Match 11.2%; Score 117.5; DB 22; Length 368;
Best Local Similarity 23.2%; Pred. No. 0.02;
Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5;

Qy 5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64
Db 163 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 220

Qy 65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122
Db 221 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 275

Qy 123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179
Db 276 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 326

RESULT 12
ABU53156
ID ABU53156 standard; Protein; 385 AA.
XX
AC ABU53156;
XX
DT 14-APR-2003 (first entry)
XX
DE Human testes-derived DKFZphtes3_2a11 homologue #16.
XX
KW Human; gene therapy; vaccine; disease treatment; detection.
XX
OS Homo sapiens.
XX
PN WO200112659-A2.
XX
PD 22-FEB-2001.
XX
PF 18-AUG-2000; 2000WO-IB01496.
XX
PR 18-AUG-1999; 99US-0149499.
PR 28-SEP-1999; 99US-0156503.
XX
PA (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI Wiemann S;
XX
DR WPI; 2001-327840/34.
XX
PT Nucleic acids having the sequences of clones isolated from libraries of
PT different human tissues, useful in recombinant DNA methodologies -
XX
PS Example III; Page 773; 1095pp; English.
XX
CC This invention describes novel polynucleotides and polypeptides isolated
CC from human cDNA libraries which can be used for gene therapy or in
CC vaccines. The polynucleotides of the invention and antibodies encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. The products of the
CC invention may also be used to identify modulators of expression and
CC activity and to down regulate expression and activity. The antibodies of
CC the invention may also be used as diagnostic agents for detecting the
CC presence of polypeptides in samples. This sequence represents a homologue
CC of a polypeptide described in the disclosure of the invention.
XX
SQ Sequence 385 AA;

Query Match 11.2%; Score 117.5; DB 22; Length 385;
Best Local Similarity 23.2%; Pred. No. 0.021;
Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5;

Qy 5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64

```
Db        165 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 222

Qy         65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122

Db        223 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 277

Qy        123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179

Db        278 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 328


RESULT 13
ABU53159
ID   ABU53159 standard; Protein; 386 AA.
XX
AC   ABU53159;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human testes-derived DKFZphtes3_2a11 homologue #19.
XX
KW   Human; gene therapy; vaccine; disease treatment; detection.
XX
OS   Homo sapiens.
XX
PN   WO200112659-A2.
XX
PD   22-FEB-2001.
XX
PF   18-AUG-2000; 2000WO-IB01496.
XX
PR   18-AUG-1999;   99US-0149499.
PR   28-SEP-1999;   99US-0156503.
XX
PA   (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI   Wiemann S;
XX
DR   WPI; 2001-327840/34.
XX
PT   Nucleic acids having the sequences of clones isolated from libraries of
PT   different human tissues, useful in recombinant DNA methodologies -
XX
PS   Example III; Page 774; 1095pp; English.
XX
CC   This invention describes novel polynucleotides and polypeptides isolated
CC   from human cDNA libraries which can be used for gene therapy or in
CC   vaccines. The polynucleotides of the invention and antibodies encoded by
CC   them may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate polypeptide expression. The products of the
CC   invention may also be used to identify modulators of expression and
CC   activity and to down regulate expression and activity. The antibodies of
CC   the invention may also be used as diagnostic agents for detecting the
CC   presence of polypeptides in samples. This sequence represents a homologue
CC   of a polypeptide described in the disclosure of the invention.
XX
SQ   Sequence   386 AA;

  Query Match           11.2%;  Score 117.5;  DB 22;  Length 386;
  Best Local Similarity   23.2%;  Pred. No. 0.021;
  Matches   41;  Conservative   23;  Mismatches   98;  Indels   15;  Gaps    5;

Qy          5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64

Db        162 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 219

Qy         65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122

Db        220 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 274

Qy        123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179

Db        275 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 325


RESULT 14
ABU53161
ID   ABU53161 standard; Protein; 387 AA.
XX
AC   ABU53161;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human testes-derived DKFZphtes3_2a11 homologue #21.
XX
KW   Human; gene therapy; vaccine; disease treatment; detection.
XX
OS   Homo sapiens.
XX
PN   WO200112659-A2.
XX
PD   22-FEB-2001.
XX
PF   18-AUG-2000; 2000WO-IB01496.
XX
PR   18-AUG-1999;   99US-0149499.
PR   28-SEP-1999;   99US-0156503.
XX
PA   (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI   Wiemann S;
XX
DR   WPI; 2001-327840/34.
XX
PT   Nucleic acids having the sequences of clones isolated from libraries of
PT   different human tissues, useful in recombinant DNA methodologies -
XX
PS   Example III; Page 775; 1095pp; English.
XX
CC   This invention describes novel polynucleotides and polypeptides isolated
CC   from human cDNA libraries which can be used for gene therapy or in
CC   vaccines. The polynucleotides of the invention and antibodies encoded by
CC   them may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate polypeptide expression. The products of the
CC   invention may also be used to identify modulators of expression and
CC   activity and to down regulate expression and activity. The antibodies of
CC   the invention may also be used as diagnostic agents for detecting the
CC   presence of polypeptides in samples. This sequence represents a homologue
CC   of a polypeptide described in the disclosure of the invention.
XX
SQ   Sequence   387 AA;

  Query Match           11.2%;  Score 117.5;  DB 22;  Length 387;
  Best Local Similarity   23.2%;  Pred. No. 0.021;
  Matches   41;  Conservative   23;  Mismatches   98;  Indels   15;  Gaps    5;

Qy          5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64

Db        180 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 237

Qy         65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122

Db        238 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 292

Qy        123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179

Db        293 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 343


RESULT 15
ABU53160
ID   ABU53160 standard; Protein; 395 AA.
XX
AC   ABU53160;
XX
```

DT 14-APR-2003 (first entry)
XX
DE Human testes-derived DKFZphtes3_2a11 homologue #20.
XX
KW Human; gene therapy; vaccine; disease treatment; detection.
XX
OS Homo sapiens.
XX
PN WO200112659-A2.
XX
PD 22-FEB-2001.
XX
PF 18-AUG-2000; 2000WO-IB01496.
XX
PR 18-AUG-1999; 99US-0149499.
PR 28-SEP-1999; 99US-0156503.
XX
PA (GEHU-) GERMAN HUMAN GENOME PROJECT.
XX
PI Wiemann S;
XX
DR WPI; 2001-327840/34.
XX
PT Nucleic acids having the sequences of clones isolated from libraries of
PT different human tissues, useful in recombinant DNA methodologies -
XX
PS Example III; Page 774-775; 1095pp; English.
XX
CC This invention describes novel polynucleotides and polypeptides isolated
CC from human cDNA libraries which can be used for gene therapy or in
CC vaccines. The polynucleotides of the invention and antibodies encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate polypeptide expression. The products of the
CC invention may also be used to identify modulators of expression and
CC activity and to down regulate expression and activity. The antibodies of
CC the invention may also be used as diagnostic agents for detecting the
CC presence of polypeptides in samples. This sequence represents a homologue
CC of a polypeptide described in the disclosure of the invention.
XX
SQ Sequence 395 AA;

Query Match 11.2%; Score 117.5; DB 22; Length 395;
Best Local Similarity 23.2%; Pred. No. 0.022;
Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5;

```
Qy          5 TTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTLG 64
              ||     |:    |   ||: |   :  ||::  :      :  | :      |  ||
Db        165 TTPSPPPTTTTTPPPTTTPSPPTTTTPSPPTITTTTPPPTTTPSPPTTTTTTPP--PTTT 222

Qy         65 VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSS 122
                |  : |:   |      |   |   |  : |     |   | ||   : ||:  |:::
Db        223 PSPPTTTPITPPTSTTTLPPTTTPSPPPTTTTTP---PPTTTPSPP--TTTTPSPPITTT 277

Qy        123 DTDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAP 179
               | ||   ||:|:      |  :   |          |: ||  :   |  :|:|
Db        278 TTPPPTTTPSSPITTTPSPPTTTMTTP------SPTTTPSSPITTTTTPSSTTTPSP 328
```

Search completed: September 24, 2003, 18:08:53
Job time : 43 secs

AAY66174

ID AAY66174 standard; Protein; 187 AA.
XX
AC AAY66174;
XX
DT 14-FEB-2000 (first entry).
XX
DE Human bladder tumour EST encoded protein 32.
XX
KW Expressed sequence tag; human; bladder; tumour; cancer; cytostatic;
KW treatment; gene therapy; EST.
XX
OS Homo sapiens.
XX
PN DE19818619-A1.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1998; 98DE-1018619.
XX
PR 21-APR-1998; 98DE-1018619.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-612028/53.
XX
PT New nucleic acid sequences expressed in bladder tumor tissue, and
PT derived polypeptides, for treatment of bladder tumor and identification
PT of therapeutic agents -
XX

PS Claim 23; Page 111; 132pp; German.
XX
CC This invention describes novel polypeptide fragments (I) and the
CC polynucleotides (II) that encode them that are highly expressed in a
CC human bladder tumour and which have cytostatic activity. (II) are used
CC for recombinant expression of (I) and to isolate complete genes. (I) are
CC used to identify agents suitable for treatment of bladder cancer, to
CC directly treat this form of cancer (including expression from gene
CC therapy vectors) or are used in a preparation for cancer treatment. (I)
CC is also used for the generation of specific antibodies. (II) are
CC identified by assembling ESTs (expressed sequence tags) from a
CC particular tissue type before comparison of expression patterns. This
CC allows a significantly longer fragment of the gene to be revealed, and
CC therefore reduces the number of failures associated with the fact that
CC ESTs from different libraries may represent different parts of the same
CC unknown gene, distorting the estimated frequency of occurrence in a
CC particular tissue. AAY66143-Y66198 represent protein fragments encoded by
CC the human bladder tumour cDNA library derived expressed sequence tag
CC (EST) fragments represented in AAZ43260-Z43309.
XX
SQ Sequence 187 AA;

Query Match 95.5%; Score 998; DB 20; Length 187;
Best Local Similarity 97.8%; Pred. No. 8.7e-82;
Matches 182; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy          4 RTTTWARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 63
              |    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 RAARGARRTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLWGAPLQPTL 61

Qy         64 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 123
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 GVVPQASVPLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHPDPPMALSRTPTRQISSSD 121

Qy        124 TDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 183
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        122 TDPPADGPSNPLCCCFHGPAFSTLNPVLRHLFPQEAFPAHPIYDLSQVWSVVSPAPSRGQ 181

Qy        184 ALRRAQ 189
              ||||||
Db        182 ALRRAQ 187
```